GLOBE LIFE INC. (GL): what the price requires

At today's price, GLOBE LIFE INC. (GL) is priced for 15.5% return on equity. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/GL

Headline

FieldValue
TickerGL
CompanyGLOBE LIFE INC.
Current price$178.61/sh
CompositionLife insurance 55% / Health insurance 25% / Investment 20%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Return on equity needed15.5%
Return on equity now19.4%
ROE gap-3.9pp
Price-to-book2.28x

Solve inputs: computed at a 9% cost of equity with 4% terminal growth over a 5-year stage, on common book equity (FY2026); each 1pp of cost of equity moves the implied ROE ~2.3pp.

How unusual the bet is: within-range

ReferenceValue
vs own history-0.15σ
cohort percentile (of 80 peers)66
sustained it ~10 years at this level58%
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.12x3expensive
Earnings0.76x2justifies
Relative0.74x3justifies
Growth1.14x1expensive

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.9%); the inversion above states its own rate.

Per-Model Detail (n=9)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)—$218.070.82xyesTBVPS $70.15 × 3.11x (ROE (TTM) 19.3% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption), credit 1.01% allowance/loans → ×0.92)
Relative ValuationRelative$168.851.06xyesP/E 11x (static sector reference · 2026-04), scenarios: 9.2x / 11.0x / 12.8x (bear / base = reference held flat / bull), EV/EBITDA 10x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$159.601.12xyesBV/sh $76.30, ROE (TTM) 19.3%, ke 9.3%
Two-Stage Excess ReturnAsset$228.210.78xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$157.281.14xyesRev $6.1B, growth 4% (input: historical growth; tapered), Terminal P/S: 2.0x / 2.3x / 2.7x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$242.870.74xyesEPS $14.45, growth 17% (input: historical EPS growth), PEG=0.72 (Undervalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset$157.511.13xyes√(22.5 × EPS $14.45 × BVPS $76.30) — Graham's conservative floor
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$466.250.38xyesEPS $14.45 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative$364.310.49xyesEPS $14.45 × (PEG 1.5 × growth 16.8% (input: historical EPS growth)) → PE 25.2x
Earnings YieldEarnings$156.221.14xyesEPS $14.45 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Share count CAGR (buyback)-5.6%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

An insurer is worth the return it earns on its capital. At $170.72 Globe Life trades at about 2.2 times book, a price that assumes it sustains a return on equity near 15%. It has recently been earning about 19%, so the price asks for less than the company is delivering.

The valuation is broadly supported. Relative-multiple, asset-based, and earnings-power lenses all sit at or above the price, and several methods land well above it. This reads as a value-supported financial, not a stretched bet.

The risk hides in the distribution engine. Agent count at the core American Income Life division fell 4% and first-quarter lapse rates ran high. Premium growth and earnings beat in Q1 2026, and guidance rose, but the agent pipeline is the variable that decides whether the franchise keeps compounding.

Bull Case

The first worry a skeptic raises about Globe Life is the distribution engine: the company sells life and supplemental health insurance through captive agent forces, and the core American Income Life division just saw average producing agent count fall 4% on weaker new-agent retention. If the sales force shrinks, the argument goes, future premium growth shrinks with it. That is a legitimate concern, and it is worth taking seriously. But the data shows a franchise still performing well above what its price assumes, which means the agent softness is a growth-rate question, not a value-destruction one. The price implies a return on equity near 15%; the company has recently been earning about 19%, and posted a 17.9% net-income ROE in the first quarter. You are being asked to pay for a return materially below what the business is actually generating.

The core economics are strong and steady. An insurer is worth the return it sustainably earns on its capital, and Globe Life's underwriting is genuinely profitable: the FY2025 10-K reports that on a normalized basis, "life underwriting margin for 2025 was $1.4 billion or 41% of premium" (FY2025 10-K, accession 0000320335-26-000090), up from $1.3 billion the prior year. A 41% underwriting margin on the life book is the signature of disciplined pricing and a sticky, predictable customer base. Q1 2026 reinforced it: net operating income rose to $3.43 per diluted share from $3.07, total premium revenue grew 6% to $1.27 billion (3% in life, 13% in health), and the company raised full-year 2026 earnings guidance to $15.40 to $15.90 per share.

The capital-return profile completes the value case. Globe Life has been steadily reducing its share count, by roughly 5% to 6% a year, which on a high-ROE book compounds per-share value efficiently: buying back stock below intrinsic value while the underlying equity earns well above its cost. The business mix is diversified across life at 55% of revenue, health at 25%, and investments at 20%, and the health book is growing double digits. Against the insurance peer set of Fidelis, Arch Capital, AXIS, Primerica, and Hartford, Globe Life is the high-ROE life-and-health specialist trading at a price that demands less than its demonstrated return. The agent-count softness is the thing to watch, but the price already discounts a meaningful slowdown the company has not yet delivered.

Bear Case

The bear case is about narrative dependency: the entire Globe Life thesis rests on the captive agent force continuing to recruit, retain, and produce, and the most recent quarter showed that engine sputtering. Average producing agent count at American Income Life, the company's largest and most important distribution channel, fell 4% on lower new-agent retention, and management was explicit that long-term growth depends on agent-count improvement. For an insurer that grows by adding agents who add policies, a shrinking sales force is the single most fragile assumption in the price. The valuation assumes the company sustains a roughly 15% return on equity for years; that return is built on premium growth, and premium growth is built on agents. If the agent pipeline does not recover, the compounding the price relies on stalls at its source.

The second fragile assumption is persistency, and it weakened too. Management described first-quarter lapse rates at American Income Life as "definitely high relative to recent experience." Lapse rates are the rate at which policies are cancelled, and they matter enormously for a life insurer: high lapses mean acquired policies leave before they pay back the cost of writing them, eroding the underwriting margin that is the heart of the bull case. The 41% normalized life underwriting margin the company reported (accession 0000320335-26-000090) is only durable if policies stay on the books. A combination of weaker agent recruitment and elevated lapses attacks both the growth and the quality of the in-force book at the same time.

The third issue is that a life insurer's reported earnings carry assumption risk that outsiders cannot easily verify. Globe Life's results normalize for "the effects of assumption changes that vary by period" (accession 0000320335-26-000090), a reminder that life-insurance accounting depends on long-term estimates of mortality, persistency, and investment returns that management sets. The investment book, 20% of revenue, also carries credit and interest-rate risk. The price already sits in the upper half of the peer group's price-to-book, so the value cushion is thinner than the headline 2.2 times multiple suggests once you account for the demonstrated ROE being above the implied. A holder is betting that the agent force recovers, lapse rates normalize, and the underwriting assumptions hold. Those are reasonable bets for a well-run insurer, but they are bets on a distribution and persistency story that just showed cracks, and the price does not offer much margin for them to disappoint.

Valuation

Globe Life is valued the way an insurer should be: off the return it earns on its capital, read through price-to-book rather than an operating multiple. At $170.72 (June 27, 2026) the market pays about 2.2 times book, which inverted at a 9.1% cost of equity over a five-year stage implies the company sustains a return on equity near 15%. Each percentage point of cost of equity moves the implied ROE by about 2.2 points. The key context is that Globe Life has recently been earning about 19.4%, comfortably above the implied 15%, so the priced-in assumption reads as within range and arguably conservative relative to the demonstrated return.

The model X-ray, built around bank-and-insurer-appropriate methods, supports the price across families. Relative valuation lands near $169, essentially at the price. The asset-based frames bracket it (simple excess return near $160, two-stage excess return near $228, Graham number near $158). The peer-multiple and earnings methods land at or well above the price (Peter Lynch near $243, Ben Graham formula near $466, earnings yield near $156). The blended cross-method anchor sits near $199, above the quote. When the methods cluster at or above the price for a financial, the read is value-supported rather than stretched.

The context that tempers the value read is the source of the ROE. The price assumes a 15% return; the company is earning 19%, but that return depends on premium growth from the agent force and on persistency in the in-force book, both of which weakened in the first quarter. The Q1 2026 results, net operating income up to $3.43 per share, premium up 6%, and raised full-year guidance to $15.40 to $15.90, are real and supportive, and the 41% normalized life underwriting margin (accession 0000320335-26-000090) confirms the core economics. The reasonable conclusion is that Globe Life is a high-ROE life-and-health insurer trading at a price that demands less than its demonstrated return, where the upside is the franchise sustaining that ROE and the risk is the agent-count and lapse softness eroding it. It is a value-supported financial whose central variable is distribution health.

Catalysts

The Q1 2026 report was the most recent catalyst and a positive one. Net income reached $3.39 per diluted share, up from $3.01, and net operating income was $3.43 per diluted share, up from $3.07. Total premium revenue rose 6% to $1.27 billion, with 3% growth in life premium and 13% in health. The company raised full-year 2026 earnings guidance to $15.40 to $15.90 per share, an increase of about $0.35 at the midpoint. Net-income return on equity was 17.9% for the quarter. (Sources: StockTitan 8-K; The Motley Fool Q1 2026 transcript; Simply Wall St.)

The distribution metrics are the catalysts to watch most closely. Average producing agent count at American Income Life fell 4% on lower new-agent retention, and management said long-term growth depends on agent-count improvement. First-quarter lapse rates at American Income Life were described as high relative to recent experience. The signals that matter going forward are agent recruitment and retention trends, lapse-rate normalization, and continued double-digit health-premium growth. Because the price assumes a roughly 15% ROE against a recently demonstrated 19%, evidence that the agent force is recovering and persistency is normalizing would support the value case, while continued softness in either would pressure the premium-growth engine the valuation depends on. (Sources: GuruFocus Q1 2026 highlights; The Motley Fool transcript; Yahoo Finance.)

Peer Cohorts (Per Segment, With Filing Citations)

Life insurance (reported)

Health insurance (reported)

Investment (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive GL report on boothcheck